These Form 3 filings are routine post-merger compliance and carry no trading signal. Monitor for the company's first earnings report as the combined entity and any forward guidance on the pipeline.
Price Chart
Executive Summary
CEO Jonathan Violin and director Heidi Henson filed initial beneficial ownership statements (Form 3) following the September 8, 2026 reverse merger between Cyclerion Therapeutics and Korsana Biosciences, which resulted in Cyclerion changing its name to Korsana Biosciences, Inc. (ticker KRSA). Violin disclosed ownership of 207,400 common shares and options for ~3 million shares, while Henson reported options for ~101,000 shares. These filings are routine post-merger Section 16 compliance and do not convey new trading information.
Key Facts
- CEO Jonathan Violin filed a Form 3 disclosing 207,400 common shares and options to purchase ~3.03 million shares (two tranches at $4.15 and $8.06 strike prices).
- Director Heidi Henson filed a Form 3 disclosing options to purchase 100,994 shares at $8.06 strike.
- The filings are required under Section 16(a) following the September 8, 2026 reverse merger where Cyclerion Therapeutics acquired Korsana Biosciences and renamed itself Korsana Biosciences, Inc.
- The new ticker symbol is KRSA, replacing the prior Cyclerion ticker CYCN.
- Violin's 207,400 common shares were received in exchange for Pre-Merger Korsana restricted stock at a 0.2074 exchange ratio; 142,588 shares remain subject to forfeiture restrictions through June 2029.
Financial Impact
No financial impact — these are administrative ownership filings required post-merger.
Risk Factors
- Post-merger integration risk for the combined Cyclerion/Korsana entity.
- Potential dilution from the ~3 million options held by the CEO alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (CYCN) — Batch item 1 | 0001193125-26-388127 |
| Document: 0001193125-26-388127-index-headers.html | 0001193125-26-388120 |
| Document: 0001193125-26-388127-index.html | 0001193125-26-388127 |
| Document: 0001193125-26-388127.txt | 0001193125-26-388127 |
| 3 Filing (CYCN) — Batch item 5 | 0001193125-26-388120 |
| Document: 0001193125-26-388120-index-headers.html | 0001193125-26-388127 |
| Document: 0001193125-26-388120-index.html | 0001193125-26-388127 |
| Document: 0001193125-26-388120.txt | 0001193125-26-388127 |
| 3 Filing (CYCN) — Batch item 9 | 0001193125-26-388127 |
| Document: 0001193125-26-388127-index-headers.html | 0001193125-26-388127 |
| Document: 0001193125-26-388127-index.html | 0001193125-26-388127 |
| Document: 0001193125-26-388127.txt | 0001193125-26-388127 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | — | awaiting T+5 | — | — |
Sep 11, 2026 6w ago | 8-K | $3.47 | awaiting T+5 | — | — |
Sep 10, 2026 6w ago | 3 | $3.47 | awaiting T+5 | — | — |
Aug 27, 2026 8w ago | 8-K | $3.99 $4.96 | ▲ +24.31% | ▲ +24.04% | — |
Aug 10, 2026 11w ago | 425 | $3.57 $4.12 | ▲ +15.41% | ▲ +15.81% | — |
Aug 3, 2026 12w ago | 425 | $3.51 $3.57 | ▲ +1.71% | ▲ +1.81% | — |
Jul 27, 2026 13w ago | EFFECT | $3.50 $3.44 | ▼ −1.71% | ▼ −2.79% | — |
Jul 10, 2026 15w ago | 425 | $3.82 $3.64 | ▼ −4.71% | ▼ −3.93% | — |
Jun 9, 2026 19w ago | S-4/A | $3.09 $3.18 | ▼ −2.91% | ▲ +0.52% | — |
Apr 30, 2026 25w ago | 10-K/A | $3.31 $3.24 | ▼ −2.11% | ▼ −3.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers